Atossa Therapeutics, Inc.
ATOS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001488039
No open-market purchases or sales by Atossa Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $2.60M in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Atossa Therapeutics, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 51 | 45 | −6 |
| Shares | 17.9M | 16.4M | −1.57M (−8.7%) |
| Value | $9.49M | $11.9M | +$2.38M (+25.1%) |
New holders (2)
Institutions that held Atossa Therapeutics, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| National Bank of Canada | 1,400 | $1.00K | 0.00% |
| Royal Bank of Canada | 20 | $0 | 0.00% |
Sold out (8)
Institutions that held Atossa Therapeutics, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Bank of Montreal | 175,699 | $105.2K |
| Citadel Advisors LLC | 71,096 | $37.6K |
| Two Sigma Securities, LLC | 38,428 | $20.3K |
| Connor, Clark & Lunn Investment Management Ltd. | 17,967 | $9.50K |
| Marathon Trading Investment Management LLC | 10,000 | $5.29K |
| Rockefeller Capital Management L.P. | 5,000 | $2.00K |
| Simplex Trading, LLC | 3,300 | $1.00K |
| Belvedere Trading LLC | 501 | $265 |